Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07070232RecruitingPhase 1/Phase 2
Testing a new drug BNT326 for advanced cancers
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+ - NCT06179160RecruitingPhase 1
Study of INCB161734 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT06606366Recruiting
Genetic tumor testing using a blood test to guide treatment
This study uses a simple blood test to look at the genetic makeup of your tumor. The results may help your doctors choose the best treatment for you. You will need to provide a tumor sample or have a biopsy.
NiceAges 18 years+ - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT07368127RecruitingPhase 1
Study of TPD3310 for advanced solid tumors
This trial tests an experimental drug called TPD3310 for people with advanced solid tumors (like lung, stomach, liver, or other cancers) that have worsened after standard treatments or cannot tolerate them. It aims to see if the drug is safe and works, especially for tumors with a specific marker called c-MET.
Beijing, Beijing MunicipalityAges 18–75 - NCT06859840Recruiting
Liver tumor detection AI study for cirrhosis patients
This trial tests an AI tool to find and classify liver tumors in people with cirrhosis or extrahepatic cancer who've had a non-contrast CT scan. You may join if you have cirrhosis or a cancer outside the liver, but not if you already have a malignant liver tumor or have had a liver transplant.
Hangzhou, ZhejiangAges 18–90 - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT07296263Enrolling by invitation
Testing portable MRI with contrast dye for brain lesions
This trial tests a new portable MRI machine that uses a standard contrast dye (gadolinium) to better see brain lesions like tumors or infections. It may help people who need an MRI but cannot easily get to a traditional scanner.
Altamonte Springs, FloridaAges 18 years+ - NCT05422690RecruitingPhase 2
Treating bile duct cancer with chemo plus Y-90 radiation
This Phase 2 study tests whether combining chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (durvalumab) with targeted Y-90 radiation can shrink inoperable intrahepatic cholangiocarcinoma tumors. It’s looking for better tumor shrinking and improved cancer control.
Fairfax, VirginiaAges 18 years+ - NCT03028246Recruiting
Safety study using focused ultrasound for certain brain tumors
This study tests whether a focused ultrasound treatment is safe for children and young adults who have a non-cancerous (benign) tumor in the center of the brain. It mainly checks safety, and it also includes monitoring before and during treatment to reduce risks like bleeding or imaging-related problems.
Washington D.C., District of ColumbiaAges 5–22 - NCT03039439Recruiting
Tissue study of parathyroid tumors to understand tumor biology
This study looks at blood and/or tissue samples from people with parathyroid problems to better understand different types of parathyroid tumors. It does not test a new medicine—instead, researchers analyze samples to learn what makes each tumor type different.
Houston, TexasAges Any age - NCT03141021Recruiting
Registry for people diagnosed with malignant peripheral nerve sheath tumors
This study is a registry, meaning it collects information from people diagnosed with malignant peripheral nerve sheath tumors (MPNST). It may help doctors learn about the condition better and improve future care.
Tampa, FloridaAges Any age - NCT03300830Recruiting
Testing tumors linked to viruses, HIV, and immune disorders
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
Bethesda, MarylandAges 18 years+ - NCT03382158Recruiting
Learn about DICER1-related tumors through a patient registry
This registry collects information about people with known or suspected DICER1-related conditions, including certain rare chest and other tumor types. It helps doctors and researchers understand these conditions better and may support future studies.
Minneapolis, MinnesotaAges birth–100 years - NCT03410394Recruiting
Registry for endocrine tumor surgery patients in Nancy
This study is a “registry,” meaning researchers collect health information from people who have surgery for certain hormone-related tumors. It may help doctors better understand outcomes and improve future care for endocrine tumors.
Vandœuvre-lès-NancyAges Any age - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT03465592RecruitingPhase 1/Phase 2
Nivolumab after mismatched bone marrow transplant for sarcoma
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
St. Petersburg, FloridaAges 1–40 - NCT03526822Recruiting
Study of new glioblastoma using MRI scans and lab markers
This study follows people newly diagnosed with glioblastoma to see how certain lab signals (MMP2 and MMP9) match up with MRI scan features. It may help doctors better understand the disease and how it appears on imaging, but it’s mainly observational.
MarseilleAges 18 years+ - NCT03551951Recruiting
Testing cancer cells and DNA in blood, urine, and bone marrow
This study looks for cancer-related cells and DNA in samples like blood, urine, and (for some) bone marrow. The goal is to see whether these tests can help detect or track solid cancers with minimal added procedures.
Columbia, MissouriAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT03655015Recruiting
Using patient tumor cells to test lung cancer treatment response
This study looks at lung cancer samples you provide to see how tumor cells respond to treatment. It may help researchers find better ways to choose treatments for lung cancer by testing response in a lab model.
San Antonio, TexasAges 18 years+ - NCT03667170RecruitingPhase 2
Study drug for certain colon cancers with MSI-H or dMMR
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.